Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA PLRG-10: Obinutuzumab for Molecular Relapse After Autologous Stem Cell Transplant in Mantle Cell Lymphoma
2015-005439-41Phase 2Terminated
- Sponsor
- Polish Lymphoma Research Group
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in mantle cell lymphoma (MCL), sponsored by Polish Lymphoma Research Group. Primary endpoint: Molecular response rate at 2 months. Started Jun 2017; status: terminated.
02
Drugs
obinutuzumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2015-005439-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005439-41.